芹菜素通过AKT/GSK3β通路抑制心脏成纤维细胞增殖与分化
该研究采用网络药理学、分子对接与动力学模拟及体外细胞实验,探究丹参抗心脏纤维化的机制。结果显示芹菜素与AKT1、GSK3β强结合,抑制TGFβ1诱导的MCFs增殖、分化及AKT1、GSK3β磷酸化。
要点
- 芹菜素是丹参抗心脏纤维化的关键活性成分之一。
- 芹菜素通过干扰AKT1和GSK3β磷酸化抑制成纤维细胞活化。
- 为丹参治疗心脏纤维化提供了网络药理学与实验依据。
核心结论
- 芹菜素与AKT和GSK3β结合并干扰其磷酸化,从而抑制TGFβ1诱导的MCFs增殖和分化。
研究设计与样本
- 研究采用网络药理学筛选丹参有效成分及心脏纤维化靶点,结合分子对接与动力学模拟,并进行体外细胞实验验证。
主要发现
- 丹参有效成分对应206个靶点,其中82个与心脏纤维化靶点重叠。
- PPI分析显示AKT1和GSK3β为枢纽靶点,富集于PI3K/AKT信号通路。
- 芹菜素为排名靠前的成分,与AKT1(度值51)和GSK3β(度值22)对应。
- 分子对接和动力学模拟显示芹菜素与AKT和GSK3β有强亲和力。
- 细胞实验显示芹菜素抑制TGFβ1诱导的MCFs活力、增殖、α-SMA和胶原I/III蛋白表达及AKT1、GSK3β磷酸化。
关键数值与推荐
- 丹参有效成分对应206个靶点,其中心脏纤维化重叠靶点82个。
- AKT1度值为51,GSK3β度值为22。
临床怎么用
- 提示丹参及其成分芹菜素可能通过AKT/GSK3β通路干预心脏纤维化,但尚需临床研究验证。
局限性
- 研究仅为体外细胞实验和计算模拟,缺乏体内实验和临床数据支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Salvia miltiorrhiza Bunge (S. miltiorrhiza) is an important Traditional Chinese herbal Medicine (TCM) used to treat cardio-cerebrovascular diseases. Based on the pharmacodynamic substance of S. miltiorrhiza, the aim of present study was to investigate the underlying mechanism of S. miltiorrhiza against cardiac fibrosis (CF) through a systematic network pharmacology approach, molecular docking and dynamics simulation as well as experimental investigation in vitro. MATERIALS AND METHODS: A systematic pharmacological analysis was conducted using the Traditional Chinese Medicine Pharmacology (TCMSP) database to screen the effective chemical components of S. miltiorrhiza, then the corresponding potential target genes of the compounds were obtained by the Swiss Target Prediction and TCMSP databases. Meanwhile, GeneCards, DisGeNET, OMIM, and TTD disease databases were used to screen CF targets, and a protein-protein interaction (PPI) network of drug-disease targets was constructed on S. miltiorrhiza/CF targets by Search Tool for the Retrieval of Interacting Genes/Proteins (STING) database. After that, the component-disease-target network was constructed by software Cytoscape 3.7. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed for the intersection targets between drug and disease. The relationship between active ingredient of S. miltiorrhiza and disease targets of CF was assessed via molecular docking and molecular dynamics simulation. Subsequently, the underlying mechanism of the hub compound on CF was experimentally investigated in vitro. RESULTS: 206 corresponding targets to effective chemical components from S. miltiorrhiza were determined, and among them, there were 82 targets that overlapped with targets of CF. Further, through PPI analysis, AKT1 and GSK3β were the hub targets, and which were both enriched in the PI3K/AKT signaling pathway, it was the sub-pathways of the lipid and atherosclerosis pathway. Subsequently, compound-disease-genes-pathways diagram is constructed, apigenin (APi) was a top ingredients and AKT1 (51) and GSK3β (22) were the hub genes according to the degree value. The results of molecular docking and dynamics simulation showed that APi has strong affinities with AKT and GSK3β. The results of cell experiments showed that APi inhibited cells viability, proliferation, proteins expression of α-SMA and collagen I/III, phosphorylation of AKT1 and GSK3β in MCFs induced by TGFβ1. CONCLUSION: Through a systematic network pharmacology approach, molecular docking and dynamics simulation, and confirmed by in vitro cell experiments, these results indicated that APi interacts with AKT and GSK3β to disrupt the phosphorylation of AKT and GSK3β, thereby inhibiting the proliferation and differentiation of MCFs induced by TGFβ1, which providing new insights into the pharmacological mechanism of S. miltiorrhiza in the treatment of CF.
引用
- Kan H, Wang P, Yang Y, et al. Apigenin inhibits proliferation and differentiation of cardiac fibroblasts through AKT/GSK3β signaling pathway. J Ethnopharmacol. 2024. PMID: 38964628. doi:10.1016/j.jep.2024.118518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。